🟢 Telix Pharmaceuticals is trading 5% up today after FDA approval of Pixclara for glioma

Telix Pharmaceuticals is trading at A$17.18 (+5.14%) after the U.S. FDA approved Pixclara on September 14, 2026.

• Pixclara became the first FDA-approved FET-PET imaging agent for glioma, enabling physicians to distinguish recurrent brain tumors from treatment-related changes.
• September 14 close: A$16.34 (+4.28%)
• The approval generated substantial investor interest, with reported intraday gains of up to 12%.